Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

(2013) T. Lange et al.   HAEMATOLOGICA

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia

(2012) S. Schnittger et al.   BLOOD

Guideline for the diagnosis and management of myelofibrosis

(2012) John T. Reilly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

Diagnostic value ofJAK2V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population

(2012) Camilla Nielsen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory

(2011) A. J. BENCH   International Journal of Laboratory Hematology

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Pitfalls in molecular diagnosis in haemato-oncology

(2011) J. Mason et al.   JOURNAL OF CLINICAL PATHOLOGY

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

(2010) H. Alchalby et al.   BLOOD

Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy

(2010) U. Siebolts et al.   JOURNAL OF CLINICAL PATHOLOGY

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia

(2009) V. De Stefano et al.   HAEMATOLOGICA

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory

(2009) Jason D. Merker et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

(2008) T. S. Larsen et al.   ANNALS OF HEMATOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

(2008) E. Lippert et al.   HAEMATOLOGICA

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

(2008) A Tefferi et al.   LEUKEMIA

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

(2008) O Benjamini et al.   LEUKEMIA